Effect of Flunixin on Ovarian Cancer Induced by DMBA in Female Wistar Rats

Introduction: Ovary cancer is one of the commonest cancers among the women. With regard to role of cyclooxygnase(COX) enzyme and production of prostaglandin type E2 in causing tumor damages in ovary cancer, application of compounds to inhibit cyclooxygnase can be effective in preventing ovary cancer. Thus, the present study was carried out to evaluate flunixin as nonselective inhibitor of Cyclooxygenase enzymes in developing ovary cancer in female Wistar rats. Methods: In this experimental research, forty eight female Wistar rats, assigned into six groups, were used. To induce cancer, 7,12 Dimethyl Benza Anthracene was directly injected into ovary. Control groups included a negative control group (no injection), a DMBA injection control group and a positive control group (DMBA+Saline injection). Ten days after administrating DMBA to the tumor, three doses (0.5, 1, 1.5 mg) of flunixin meglumine were injected into the three case groups every third day. The comparison between groups was made by using one-way ANOVA. Results: The mean weight of tumors significantly decreased in drug receiving groups, compared to positive control and DMBA control groups. The mean weight of ovary in the three groups receiving flunixin did not show any significant difference, compared with the negative control (natural) group (P>0.05). Conclusion: This study confirms the positive effect of the flunixin in treating the ovary cancer. The microscopic slices of ovary tissues in the experimental (drug receiving) groups indicate that cancerous cells are decreasing so that the cells tend to gain their own normal order again.